跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 18,798 条关于
“EGFR tyrosine kinase inhibitors”
全部
18,798
临床试验
9,366
药物
3,739
机构
23
资讯
5,670
2个月前
EGFR-TKIs Pose Highest Cardiovascular Risk Among Tyrosine Kinase Inhibitors, Meta-Analysis Finds
2年前
Rilertinib Demonstrates Superior Survival in EGFR-Mutated NSCLC in Phase 3 Trial
去年
Anlotinib Combined with EGFR-TKIs Shows Promise in Extending Progression-Free Survival in Advanced NSCLC
去年
Olverembatinib Shows Promise in TKI-Resistant CML and Ph+ ALL
去年
CTC-Guided EGFR Inhibitor Therapy Achieves 14-Month Response in Metastatic Hepatocellular Carcinoma
9个月前
Tyrosine Kinase Inhibitors and Gene Therapies Show Promise for Wet AMD Treatment
去年
TKIs Show Promise in Asymptomatic Brain Metastases of EGFR-Mutated NSCLC
去年
Ruxolitinib Plus TKI Therapy Shows Promise in Chronic Myeloid Leukemia
去年
DualityBio's HER3-Targeting ADC DB-1310 Receives FDA Fast Track Designation for EGFR-Mutant Lung Cancer
2年前
Patritumab Deruxtecan Shows PFS Improvement in EGFR-Mutated NSCLC
第 1 页，共 567 页
上一页
下一页
